{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:19:24Z","timestamp":1785863964389,"version":"3.56.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jcf.2022.12.007","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T15:27:43Z","timestamp":1671550063000},"page":"414-419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Lived experiences of people with cystic fibrosis that were not eligible for elexacaftor-tezacaftor-ivacaftor (ETI): A qualitative study"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2746-4086","authenticated-orcid":false,"given":"Francesco","family":"Milo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Ciciriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4333-791X","authenticated-orcid":false,"given":"Federico","family":"Alghisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Tabarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jcf.2022.12.007_bib0001","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jcf.2016.11.002","article-title":"Environmental scan of cystic fibrosis research worldwide","volume":"16","author":"Kelly","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2022.12.007_bib0002","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jcf.2008.03.007","article-title":"The prevalence of cystic fibrosis in the European Union","volume":"7","author":"Farrell","year":"2008","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2022.12.007_bib0003","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.10","article-title":"Cystic fibrosis","volume":"1","author":"Ratjen","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"S40","key":"10.1016\/j.jcf.2022.12.007_bib0004","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1002\/ppul.23244","article-title":"Tackling the increasing complexity of CF care","volume":"50","author":"Sawicki","year":"2015","journal-title":"Pediatr Pulmonol"},{"issue":"9","key":"10.1016\/j.jcf.2022.12.007_bib0005","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s00431-021-04168-y","article-title":"A new era for people with cystic fibrosis","volume":"180","author":"Bierlaagh","year":"2021","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jcf.2022.12.007_bib0006","first-page":"1","article-title":"Discovery of CFTR modulators for the treatment of cystic fibrosis","author":"Lopes-Pacheco","year":"2021","journal-title":"Expert Opin Drug Discovery"},{"issue":"5","key":"10.1016\/j.jcf.2022.12.007_bib0007","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3390\/ph15050606","article-title":"Elexacaftor-tezacaftor-ivacaftor as a final frontier in the treatment of cystic fibrosis: definition of the clinical and microbiological implications in a case-control study","volume":"15","author":"Migliorisi","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jcf.2022.12.007_bib0008","article-title":"Efficacy and safety of triple combination cystic fibrosis transmembrane conductance regulator modulators in patients with cystic fibrosis: a meta-analysis of randomized controlled trials","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2022.12.007_bib0009","first-page":"1","volume":"45","author":"Campagna","year":"2021"},{"issue":"1","key":"10.1016\/j.jcf.2022.12.007_bib0010","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-022-01825-2","article-title":"Lived experiences of individuals with cystic fibrosis on CFTR-modulators","volume":"22","author":"Page","year":"2022","journal-title":"BMC Pulmonary Med"},{"issue":"10","key":"10.1016\/j.jcf.2022.12.007_bib0011","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.3390\/ijerph19106114","article-title":"Evaluating the effect of kaftrio on perspectives of health and wellbeing in individuals with cystic fibrosis","volume":"19","author":"Aspinall","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jcf.2022.12.007_bib0012","article-title":"The psychological implications and health risks of cystic fibrosis pre- and post- CFTR modulator therapy","author":"Keyte","year":"2022","journal-title":"Chronic Illness"},{"issue":"1","key":"10.1016\/j.jcf.2022.12.007_bib0013","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1207\/s15326985ep3901_4","article-title":"Evolution of a constructivist conceptualization of epistemological reflection","volume":"39","author":"Baxter Magolda","year":"2004","journal-title":"Educ Psychologist"},{"key":"10.1016\/j.jcf.2022.12.007_bib0014","doi-asserted-by":"crossref","unstructured":"Weenink E, Bridgman T. Taking subjectivity and reflexivity seriously: Implications of social constructionism for researching volunteer motivation. 2020.","DOI":"10.26686\/wgtn.12735962.v1"},{"issue":"9","key":"10.1016\/j.jcf.2022.12.007_bib0015","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","article-title":"Standards for reporting qualitative research","volume":"89","author":"O'Brien","year":"2014","journal-title":"Acad Med"},{"issue":"2","key":"10.1016\/j.jcf.2022.12.007_bib0016","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"issue":"2","key":"10.1016\/j.jcf.2022.12.007_bib0017","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1468794112468475","article-title":"Now I see it, now I don't: researcher's position and reflexivity in qualitative research","volume":"15","author":"Berger","year":"2013","journal-title":"Qual Res"},{"issue":"4","key":"10.1016\/j.jcf.2022.12.007_bib0018","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/026999300402781","article-title":"On bad decisions and disconfirmed expectancies: the psychology of regret and disappointment","volume":"14","author":"Zeelenberg","year":"2000","journal-title":"Cognit Emotion"},{"key":"10.1016\/j.jcf.2022.12.007_bib0019","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fnhum.2010.00235","article-title":"The impact of disappointment in decision making: inter-individual differences and electrical neuroimaging","volume":"4","author":"Tzieropoulos","year":"2011","journal-title":"Front Hum Neurosci"},{"key":"10.1016\/j.jcf.2022.12.007_bib0020","series-title":"A theory of disappointment","author":"Chauveau","year":"2009"},{"issue":"5","key":"10.1016\/j.jcf.2022.12.007_bib0021","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/ppul.25859","article-title":"A survey: understanding the health and perspectives of people with CF not benefiting from CFTR modulators","volume":"57","author":"Kramer-Golinkoff","year":"2022","journal-title":"Pediatr Pulmonol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932201428X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932201428X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:48:07Z","timestamp":1761601687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919932201428X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S156919932201428X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2022.12.007","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lived experiences of people with cystic fibrosis that were not eligible for elexacaftor-tezacaftor-ivacaftor (ETI): A qualitative study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2022.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}